Resmed Inc Gets a Hold Rating from BMO Capital

By Austin Angelo

In a report issued on July 10, Joanne Wuensch from BMO Capital reiterated a Hold rating on Resmed Inc (NYSE: RMD), with a price target of $100. The company’s shares closed yesterday at $107.57, close to its 52-week high of $108.55.

According to TipRanks.com, Wuensch is a 5-star analyst with an average return of 10.8% and a 68.9% success rate. Wuensch covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Zimmer Biomet Holdings, and Baxter International.

Currently, the analyst consensus on Resmed Inc is a Hold with an average price target of $86.50.

See today’s analyst top recommended stocks >>

Based on Resmed Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly net profit of $110 million. In comparison, last year the company had a net profit of $102 million.

Based on the recent corporate insider activity of 100 insiders, corporate insider sentiment is neutral on the stock. Most recently, in May 2018, Gary Pace, a Director at RMD sold 28,403 shares for a total of $2,765,600.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ResMed, Inc. engages in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders including sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases.